Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Inclusion Criteria

• •Adult male or female, at least ≥ 65 years old; or 20 to 64 years old and have at least 1 of the following:
• •* Cumulative Illness Rating Scale (CIRS) score \> 6.
• •* Creatinine clearance (CrCl) estimated \< 70 mL/min using Cockcroft-Gault equation.
• •Must have measurable nodal disease (by computed tomography \[CT\]), defined as at least one lymph node \> 1.5 cm in longest diameter.
• •Diagnosed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that requires treatment according to the Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.